- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Pierre Blanchard explores testosterone recovery patterns following androgen deprivation therapy in prostate cancer treatment. The presentation explores key factors affecting recovery time while discussing implications for patient quality of life and potentially oncological outcomes, emphasizing the importance of careful monitoring...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores key questions surrounding androgen deprivation therapy. The experts debate testosterone replacement safety after ADT and the controversy between GnRH agonists and antagonists in cardiovascular outcomes, emphasizing that patient background and risk factor management may influence results more than drug ch...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), a panel discussion explores treatment recommendations and sequencing for metastatic castration-resistant prostate cancer. The panel shows strong support (92%) for PARP inhibitor plus AR pathway inhibitor combination in first-line mCRPC for BRCA2 alterations, while favoring combination approaches including metastasis-directed therap...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Niven Mehra discusses current guidelines and practical considerations for tumor genomic profiling in advanced prostate cancer. The presentation examines the advantages and limitations of different testing approaches, emphasizing tissue biopsies' high success rates while addressing concerns about intratumoral heterogeneity and the e...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Ian Davis addresses the complexities of treatment sequencing following doublet therapy for metastatic hormone-sensitive prostate cancer. The presentation explains that treatments like docetaxel, abiraterone, and enzalutamide show greater benefits in hormone-sensitive states than in CRPC, while warning against approaches that might...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Karim Fizazi examines treatment sequencing options following triplet therapy in metastatic castration-sensitive prostate cancer. The presentation emphasizes personalizing treatment based on clinical and biological markers while addressing key scenarios of AR mutations, bypass pathways, and lineage plasticity with neuroendocrine dif...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Joaquin Mateo discusses PARP inhibitors in BRCA-mutated prostate cancer treatment. He explores their effectiveness against tumors with impaired homologous recombination repair while highlighting key findings from PROfound and TRITON3 trials. Biographies: Joaquin Mateo, MD, PhD, Medical Oncologist, Prostate Cancer Translational Rese...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Johann Sebastian de Bono discusses the complexities of PARP inhibition in prostate cancer treatment. The presentation highlights concerns about widespread PARP inhibitor use without proper patient selection and raises awareness about potential long-term risks, while emphasizing the need for improved testing methods and careful cons...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Elena Castro provides a comprehensive overview of PARP inhibitor safety profiles in prostate cancer treatment. The presentation outlines specific management strategies while addressing the rare risk of myelodysplastic syndrome and acute myeloid leukemia, concluding that for patients with BRCA or HRR alterations, the benefits outwei...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Silke Gillessen, Aurelius Omlin, and a panel of experts engage in a comprehensive discussion about managing biochemical recurrence in prostate cancer patients. They cover key scenarios including PSA persistence after radical prostatectomy, timing of salvage radiotherapy, and the role of PSMA PET imaging. Biographies: Silke Gillesse...
|
